Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Pancreatic Cancer
Interventions
DRUG

Neoadjuvant chemoradiation

"* Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* 4 weeks rest, re-evaluation for resectability~* operation~* start maintenance chemotherapy within 4\~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"

PROCEDURE

Upfront surgery

"* Operation at time of diagnosis~* Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* start maintenance chemotherapy within 4\~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"

Trial Locations (5)

410-769

Center for Liver Cancer, National Cancer Center, Goyang-si

463-707

Seoul National University Bundang Hospital, Seongnam

110-744

Seoul National University Hospital, Seoul

135-710

Samsung Medical Center, Seoul

Unknown

Gangnam Severance Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT01458717 - Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter